Now That Its Shares Have Cooled Off A Bit, Is It Time To Buy This “Flaming Hot” Biotech Stock?
Shares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a…